Treatment of Acute Renal Allograft Rejection with Alemtuzumab

Introduction: Steroid-resistant renal allograft rejections are commonly treated with a 10-14 days course of antithymocyte globulin (ATG). Data on the use of alemtuzumab for treatment of acute rejection are sparse. We assessed whether alemtuzumab could be an effective, safe, and more convenient alternative for ATG in the treatment of acute renal allograft rejection. Methods: We retrospectively analyzed all adult renal transplant patients treated...